Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma
Status:
Withdrawn
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to further define an effective strategy for people with
renal cell carcinoma and to learn the safety and effectiveness of two different types of
sunitinib-refractory treatments: Bevacizumab alone or a combination of sunitinib and
bevacizumab. Sunitinib is an FDA approved drug and is currently one of the standard
treatments for advanced renal cell carcinoma. However, some people who receive this treatment
do not respond to treatment or they stop responding to treatment. Bevacizumab is an FDA
approved drug used for the treatment of several cancers however, is not yet approved for use
in renal cell carcinoma.